Indian journal of pediatrics · 2026
Immune Reconstitution in Pediatric Patients Post Autologous Stem Cell Transplantation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bathwar Nupur, Batra Satyendra, Kurup Arjun, Meena Jagdish Prasad, Deepak Rakesh Kumar, Tanwar Pranay, Pushpam Deepam, Coshic Poonam, Mohanty Sujata, Bakhshi Sameer, Seth Rachna, Gupta Aditya Kumar
Аннотация
OBJECTIVES: To determine the prevalence of hypogammaglobulinemia at three months post-ASCT and characterize humoral and cellular immune reconstitution kinetics.
METHODS: Twelve pediatric patients (median age 10 y) undergoing ASCT for high-risk neuroblastoma (n = 4) or relapsed / refractory Hodgkin lymphoma (n = 8) at AIIMS New Delhi (February 2024-November 2025) were prospectively followed. Serial immunoglobulin levels and lymphocyte subsets were measured at baseline and on days +15, +30, +90, +180. Linear mixed-effects models analyzed trajectories on percentages and absolute counts.
RESULTS: Median IgG at day +90 was 1070 mg/dL (IQR 901-1244). Hypogammaglobulinemia (IgG <500 mg/dL) occurred in 2 of 12 patients (16.7%; 95% CI: 2.1-48.4); both had received rituximab pre-transplant. None of the nine rituximab-naïve patients developed hypogammaglobulinemia. IgM showed a non-significant upward trend at day +90 (p = 0.054), reaching significance at day +180 (p <0.05). Absolute-count analysis demonstrated CD8+ expansion at day +30 (Δ = +652 cells/µL; p = 0.001), profound B-cell depletion at days +15 and +30 (both p <0.01), and a CD4+ deficit at day +90 (Δ = -198 cells/µL; p = 0.017). NK-cell counts remained stable.
CONCLUSIONS: Pediatric ASCT recipients demonstrated predictable immune recovery; hypogammaglobulinemia at three months was confined to rituximab-exposed patients, supporting risk-stratified post-transplant immunoglobulin surveillance and revaccination.
METHODS: Twelve pediatric patients (median age 10 y) undergoing ASCT for high-risk neuroblastoma (n = 4) or relapsed / refractory Hodgkin lymphoma (n = 8) at AIIMS New Delhi (February 2024-November 2025) were prospectively followed. Serial immunoglobulin levels and lymphocyte subsets were measured at baseline and on days +15, +30, +90, +180. Linear mixed-effects models analyzed trajectories on percentages and absolute counts.
RESULTS: Median IgG at day +90 was 1070 mg/dL (IQR 901-1244). Hypogammaglobulinemia (IgG <500 mg/dL) occurred in 2 of 12 patients (16.7%; 95% CI: 2.1-48.4); both had received rituximab pre-transplant. None of the nine rituximab-naïve patients developed hypogammaglobulinemia. IgM showed a non-significant upward trend at day +90 (p = 0.054), reaching significance at day +180 (p <0.05). Absolute-count analysis demonstrated CD8+ expansion at day +30 (Δ = +652 cells/µL; p = 0.001), profound B-cell depletion at days +15 and +30 (both p <0.01), and a CD4+ deficit at day +90 (Δ = -198 cells/µL; p = 0.017). NK-cell counts remained stable.
CONCLUSIONS: Pediatric ASCT recipients demonstrated predictable immune recovery; hypogammaglobulinemia at three months was confined to rituximab-exposed patients, supporting risk-stratified post-transplant immunoglobulin surveillance and revaccination.